Australia’s rescheduling of psilocybin for medical use

In February 2023, Australia’s Therapeutic Goods Administration (TGA) announced a landmark decision to reschedule psilocybin, becoming the first national regulator in the world to permit the compound to be prescribed as a psychiatric treatment. Effective from 1 July 2023, psilocybin was moved from Schedule 9 (prohibited substances) to Schedule 8 (controlled drugs) to allow its use specifically for treatment-resistant depression. This shift represents a significant pivot in global drug policy, transitioning psilocybin from a strictly prohibited compound to a regulated medical option under highly specific conditions. While Australia explores this new medical pathway, psilocybin remains a Schedule 7 substance in South Africa under the Medicines and Related Substances Act, leaving no legal avenue for therapeutic use locally. Understanding the Australian model offers important context for how other regulators, including South Africa’s SAHPRA, might approach psychedelics in the future.

The TGA Decision and Schedule Changes

The TGA is Australia’s equivalent of SAHPRA, responsible for regulating therapeutic goods. Its scheduling system classifies medicines and poisons based on their potential risk and medical utility. For decades, psilocybin sat in Schedule 9, a category for substances with a high potential for abuse and no accepted medical use. The TGA’s decision to down-schedule psilocybin to Schedule 8 acknowledges that, in very specific clinical contexts, there is an emerging accepted medical use. Schedule 8 drugs are controlled substances that can be prescribed but require strict monitoring due to their potential for misuse.

It is crucial to note that this rescheduling is highly conditional. For all uses outside of authorised psychiatric treatment for treatment-resistant depression, psilocybin remains a Schedule 9 prohibited substance. The TGA also rescheduled MDMA for post-traumatic stress disorder (PTSD) in the same ruling, marking a broader shift in how certain psychedelics are viewed by medical regulators. The decision means that psilocybin is not legally available for general use or self-administration; it is recognised strictly as a medicine to be administered within a defined clinical framework.

Strict Authorised Prescribing Conditions

The rescheduling does not mean that general practitioners can write standard prescriptions for psilocybin. Access is strictly limited to authorised psychiatrists who must navigate a rigorous approval process. To prescribe psilocybin, a psychiatrist must apply to the TGA under either the Authorised Prescriber (AP) scheme or the Special Access Scheme (SAS). These pathways are designed for medicines that have not yet been fully registered for general use, requiring the treating physician to justify the clinical need and ensure appropriate oversight.

Furthermore, the TGA’s framework mandates that the administration of psilocybin cannot occur at home. It must take place in a clinically controlled environment, such as a hospital or specialised clinic, where the patient can be continuously monitored by medical professionals. This requirement reflects the conditions of clinical trials, where the therapeutic effects are paired with structured psychological support and oversight to manage any adverse reactions. The model ensures that the medicine is handled purely as a clinical intervention rather than a take-home pharmaceutical.

The Clinical Evidence and Debate

The TGA’s decision was driven by a growing body of evidence suggesting that psilocybin, when combined with psychological support, can produce rapid and sustained antidepressant effects in individuals who have not responded to conventional treatments. Research from globally recognised institutions, such as Imperial College London and Johns Hopkins University, has demonstrated significant reductions in depression symptoms following psilocybin-assisted therapy. However, the decision has not been without controversy within the medical and scientific communities.

Some medical professionals and psychiatric associations argued that the rescheduling was premature. Critics noted that the current evidence base largely relies on small-scale Phase 2 clinical trials, which often lack the long-term follow-up and placebo-controlled rigour of Phase 3 trials. There were concerns that moving to clinical practice before larger trials are completed could expose patients to unknown risks and make it difficult to collect further safety data. Proponents, on the other hand, argue that the severity of treatment-resistant depression necessitates urgent action, and that the TGA’s strict prescribing conditions adequately mitigate potential risks while providing access to those in need.

Lessons for South African Policy

The Australian model provides a concrete case study for how a regulator can create a narrow, legally protected channel for therapeutic access without legalising a substance for broader societal use. In South Africa, psilocybin is currently classified as a Schedule 7 substance under the Medicines Act, the most restrictive category, making any medical research or therapeutic application legally complex. While South African courts have previously intervened to force regulatory reform—most notably regarding the private use of cannabis—there is currently no equivalent legal pathway for psilocybin.

The TGA’s approach demonstrates how a regulatory body can respond to emerging scientific data by implementing tightly controlled frameworks rather than maintaining blanket prohibition. For South African policymakers and advocates, the Australian precedent highlights the importance of developing domestic clinical research. Regulatory shifts are typically built upon robust, locally relevant medical evidence and clear public health frameworks, suggesting that South Africa’s path to psilocybin reform would require active engagement with SAHPRA and the medical community.